Nitin Jain, James M. Reuben, Hagop Kantarjian, Changping Li, Hui Gao, Bang-Ning Lee, Evan N. Cohen, Theresa Ebarb, David A. Scheinberg and Jorge Cortes Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease Cancer 115
Version of Record online: 17 JUN 2009 | DOI: 10.1002/cncr.24468
The use of heteroclitic peptides in chronic myelogenous leukemia may contribute to disruption in immune tolerance. In this study, 3 of 10 patients achieved a 1-log reduction in Bcr-Abl transcript levels.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field